Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of “Buy” from Brokerages

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) have earned an average recommendation of “Buy” from the seven ratings firms that are presently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $6.33.

CNTX has been the subject of several recent research reports. Citizens Jmp raised Context Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 8th. D. Boral Capital reiterated a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a research report on Wednesday, January 15th. Finally, JMP Securities started coverage on shares of Context Therapeutics in a report on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 target price on the stock.

Context Therapeutics Price Performance

Shares of CNTX opened at $0.84 on Thursday. Context Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.75. The stock has a market cap of $63.22 million, a price-to-earnings ratio of -0.93 and a beta of 2.06. The firm has a 50 day simple moving average of $0.97 and a 200-day simple moving average of $1.64.

Institutional Trading of Context Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Shay Capital LLC acquired a new position in shares of Context Therapeutics during the 4th quarter valued at about $52,000. MPM Bioimpact LLC purchased a new stake in Context Therapeutics in the fourth quarter valued at approximately $15,441,000. Millennium Management LLC increased its position in Context Therapeutics by 24.2% during the fourth quarter. Millennium Management LLC now owns 178,718 shares of the company’s stock worth $188,000 after purchasing an additional 34,835 shares during the last quarter. Citadel Advisors LLC purchased a new stake in shares of Context Therapeutics during the 4th quarter valued at $31,000. Finally, Allostery Investments LP purchased a new stake in shares of Context Therapeutics during the 4th quarter valued at $998,000. 14.03% of the stock is owned by institutional investors and hedge funds.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.